Antimicrobial platform - BTX 1801 Phase 2a clinical study, page-67

Do we even know if US investors are still in, they may have sold out with big drop last fall. Antimicrobial drug development is a hard sell, most big Pharma abandoned that years ago and smaller companies are pushing for more government funding to support the space. Drug Resistance is result
of indiscriminate over use and prescribers have begun to change their behaviors and look to limit antibiotic prescriptions making commercial success hard for the companies still in the game. Upside for this is for doctors to revert to old behavior and broadly prescribe which creates a huge dilemma for payers and doctors to go against common standards. Success going forward depends on keeping and attracting big money investor funds so would be great ask the question at the AR if they remain onboard.

https://www.antimicrobialsworkinggroup.org/antimicrobial-resistance/